US patent office grants Charpentier CRISPR patent

The US Patent Office has granted the Charpentier/Doudna key CRISPR patent, which was previously involved in an interference proceeding.
 

Read more

European Parliament greenlights Horizon Europe priorities

As a first result of the trilogue on the €100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.

Read more

Biotechpharma UAB expanding production

Lituanian CDMO Biotechpharma UAB has invested €50m in order to expand its production capacity to 5000 litres.

Read more

Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.

Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.

Read more

Treating diabetes by mimicking gut bacteria effects

Researchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.

Read more

Immunic lists at Nasdaq

Chronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies.
 

Read more

Preventing virus infections in newborns

Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.

Read more

Evotec and Indivumed join forces in CRC

Evotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments.

Read more

Theranexus colloborates with AI expert Dyliss

Lyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).

Read more

uniQure Receives FDA Fast Track Designation for AMT-130

Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019.

Read more